Search

Your search keyword '"Pineau, Fanny"' showing total 47 results
Start Over Author "Pineau, Fanny"
47 results on '"Pineau, Fanny"'

2. Personality assessment with Temperament and Character Inventory in Parkinson's disease

Author

Moreau, Caroline, Defebvre, Pr Luc, Carriere, Dr Nicolas, Grolez, Dr Guillaume, Baille, Dr Guillaume, Kreisler, Dr, Jean-Pierre Pruvo, Pr, Leclerc, Pr, Lopes, Dr Renaud, Viard, Dr Romain, Kuchcinski, Dr Gregory, Dumont, Mr Julien, Dujardin, Pr Kathy, Delliaux, Mme M., Brion, Mrs M., Touzet, Dr Gustavo, Reyns, Pr Nicolas, Delval, Pr Arnaud, Santraine, Mrs Valerie, Pleuvret, Mrs Marie, Dautrevaux, Mrs Nolwen, Laugeais, Mr Victor, Ouk, Thavarak, Potey, Camille, Leclercq, Celine, Gers, Elise, Corvol, Jean-Christophe, Marie-Vidailhet, Hainque, Elodie, Welter, Marie-Laure, Lacomblez, Lucette, Grabli, David, Roze, Emmanuel, Worbe, Yulia, Delorme, Cécile, You, Hana, Ihle, Jonas, Guimeraes-Costa, Raquel, Cormier-Dequaire, Florence, Méneret, Aurélie, Hartmann, Andréas, Mariani, Louise-Laure, Lehericy, Stéphane, Czernecki, Virginie, Pineau, Fanny, Bozon, Frédérique, Huiban, Camille, Benchetrit, Eve, Karachi, Carine, Navarro, Soledad, Cornu, Philippe, Welaratne, Arlette, Dongmo-Kenfack, Carole, Mantisi, Lise, Jarry, Nathalie, Aix, Sophie, Lefort, Carine, Rouaud, Dr Tiphaine, Damier, Pr Philippe, Derkinderen, Pr Pascal, Anne-Gaelle Corbille, Dr, Calvier-Auffray, Dr Elisabeth, Rocher, Mrs Laetitia, Anne-Laure Deruet, Mrs, Sylvie, Dr Raoul, Vincent, Dr Roualdes, Le Dily Séverine, Mrs, Marques, Dr Ana, Debilly, Dr Berangere, Durif, Pr Franck, Derost, Dr Philippe, Beal, Dr Charlotte, Chassain, Carine, Delaby, Laure, Vidal, Tiphaine, Jacques Lemaire, Pr Jean, Rieu, Isabelle, Durand, Elodie, Eusebio, Pr Alexandre, Jean-Philippe Azulay, Pr, Witjas, Dr Tatiana, Fluchère, Dr Frédérique, Grimaldi, Dr Stephan, Girard, Pr Nadine, Delfini, Marie, Carron, Dr Romain, Regis, Pr Jean, Spatola, Dr Giorgio, Magnaudet, Camille, Solène, Dr Ansquer, Isabelle, Dr Benatru, Olivier, Dr Colin, Houeto Jl, Pr, Remy, Pr Guillevin, Anne, Mrs Fradet, Manssouri, Mrs Anziza, Sophie, Mrs Blondeau, Philippe, Dr Richard, Philippe, Dr Cam, Philippe, Dr Page, Benoit, Pr Bataille, Emilie, Mrs Rabois, Annie, Mrs Guillemain, Sophie, Dr Drapier, Leh, Dr Frédérique, Bonnet, Dr Alexandre, Vérin, Pr Marc, Jean-Christophe Ferré, Dr, François Houvenaghel, Mr Jean, Haegelen, Pr Claire, Kestens, Mrs Francoise, Ory, Mrs Solenn, Burbaud, Pr Pierre, Damon-Perriere, Dr Nathalie, Meissner, Pr Wassilios, Tison, Pr Francois, Bannier, Dr Stéphanie, Krim, Dr Elsa, Guehl, Pr Dominique, Molinier-Blossier, Sandrine, Ollivier, Morgan, Lacoste, Marion, Auzou, Nicolas, Bonnet, Marie, Cuny, Pr Emmanuel, Engelhardt, Dr Julien, Branchard, Olivier, Huet, Clotilde, Blanchard, Julie, Olivier, Pr Rascol, Brefel Courbon, Dr Christine, Ory Magne, Dr Fabienne, Simonetta Moreau, Dr Marion, Arbus, Pr Christophe, Bonneville, Pr Fabrice, Albert Lotterie, Dr Jean, Sarrail, Marion, Scotto d’Apollonia, Charlotte, Chaynes, Pr Patrick, Caire, Pr François, Harroch, Estelle, Maltete, Pr David, Lefaucheur, Dr Romain, Fetter, Dr Damien, Magne, Dr Nicolas, Bioux, Mrs Sandrine, Loubeyre, Mrs Maud, Bliaux, Mrs Evangéline, Pouliquen, Mrs Dorothée, Derrey, Pr Stéphane, Vernon, Mrs Linda, Ziegler, Dr Frédéric, Anheim, Mathieu, Lagha-Boukbiza, Ouhaid, Tranchant, Christine, Gebus, Odile, Montaut, Solveig, Kremer, S., Longato, Nadine, Phillips, Clélie, Voirin, Jimmy, Santin, Marie des Neiges, Chaussemy, Dominique, Mengin, Dr Amaury, Giordana, Dr Caroline, Marsé, Dr Claire, Mondot, Lydiane, Giordana, Bruno, Kardous, Robin, Bailet, Bernadette, Joly, Héloise, Fontaine, Denys, Leplus, Dr Aurélie, Faustini, Amélie, Ferrier, Vanessa, Krystkowiak, Pr Pierre, Tir, Dr Mélissa, Jean-Marc Constans, Pr, Wannepain, Sandrine, Seling, Audrey, Lefranc, Dr Michel, Blin, Stéphanie, Schuler, Béatrice, Thobois, Pr Stephane, Danaila, Dr Teodor, Laurencin, Dr Chloe, Berthezene, Pr Yves, Ameli, Dr Roxana, Klinger, Helene, Polo, Dr Gustavo, Mertens, Patrick, Nunes, A., Metereau, Elise, Hopes, Dr Lucie, Frismand, Dr Solène, Schmitt, Dr Emmanuelle, Meyer, Mrs Mylène, Dillier, Mrs Céline, Colnat, Pr Sophie, Chatelain, Mrs Anne, Philippe Brandel, Dr Jean, Hubsch, Dr Cécile, Karsenti, Dr Patte, Lebouteux, Dr Marie, Ziegler, Dr Marc, Delmaire, Dr Christine, Savatowky, Dr Julien, Vrillac, Mrs Juliette, Nakache, Mrs Claire, D'Hardemare, Dr Vincent, Belamri, Mr Lhaouas, Mesnage, Dr Valérie, Bonnet, Dr Cécilia, Correa Lino, Dr Jarbas, Jr., Decrocq, Dr Camille, Boulin, Dr Anne, Barre, Mrs Inès, Manouvrier, Mrs Jordane, Gardel, Dr Bérénice, Jarraya, Pr Béchir, Ziz, Mrs Catherine, Prette, Mrs Lydie, Douzane, Mr Hassen, Gay, David, Bonicel, Robin, El Mountassir, Fouzia, Fischer, Clara, Mangin, Jean-François, Chupin, Marie, Cointepas, Yann, Accart, Bertrand, Gelé, Patrick, Fievet, Florine, Chabel, Matthieu, Derenaucourt, Virginie, Facon, Loïc, Njosse, Yanick Tchantchou, Deplanque, Dominique, Duhamel, Alain, Djemmane, Lynda, Duflot, Florence, Boussac, Mathilde, Arbus, Christophe, Colin, Olivier, Laurencin, Chloé, Eusebio, Alexandre, Corvol, Jean Christophe, Versace, Nathalie, Rascol, Olivier, Rousseau, Vanessa, Ory-Magne, Fabienne, Fabbri, Margherita, Rolland, Anne-Sophie, Jarraya, Béchir, Maltête, David, Drapier, Sophie, Marques, Ana-Raquel, Wirth, Thomas, Meyer, Mylène, Tir, Mélissa, Rouaud, Tiphaine, Devos, David, and Brefel-Courbon, Christine

Published
2022
Full Text
View/download PDF

3. Behavioural disinhibition in frontotemporal dementia investigated within an ecological framework

Author

Batrancourt, Bénédicte, Azuar, Carole, Dubois, Bruno, Lecouturier, Karen, Araujo, Carla M., Janvier, Estelle, Jourdain, Aline, Rametti-Lacroux, Armelle, Coriou, Sophie, Brochard, Vanessa B., Gaudebout, Cécile, Ferrand-Verdejo, Johan, Bonnefous, Louis, Pochan-Leva, Flore, Jeanne, Lucie, Joulié, Mathilde, Provost, Myriam, Renaud, Rozenn, Hachemi, Sarah, Guillemot, Vincent, Bendetowicz, David, Carle, Guilhem, Socha, Julie, Pineau, Fanny, Marin, Frédéric, Liu, Yongjian, Mullot, Pierre, Mousli, Aymen, Blossier, Armelle, Visentin, Giulia, Tanguy, Delphine, Godefroy, Valérie, Sezer, Idil, Boucly, Mathilde, Cabrol-Douat, Blandine, Odobez, Raphaëlle, Marque, Constance, Tessereau-Barbot, Daphné, Raud, Anaïs, Funkiewiez, Aurélie, Chamayou, Céline, Cognat, Emmanuel, Le Bozec, Manon, Bouzigues, Arabella, Le Du, Vincent, Bombois, Stéphanie, Simard, Camille, Fulcheri, Paolo, Guitton, Hortense, Peltier, Caroline, Lejeune, François-Xavier, Jorgensen, Lars, Mariani, Louise-Laure, Corvol, Jean-Christophe, Valero-Cabre, Antoni, Garcin, Béatrice, Volle, Emmanuelle, Le Ber, Isabelle, Migliaccio, Raffaella, Levy, Richard, Saracino, Dario, Morandi, Xavier, and Jannin, Pierre

Published
2022
Full Text
View/download PDF

5. Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations

Author

Benchetrit, Eve, Delaby, Laure, Berthet, Deborah, Danjou, Fabrice, Vidaihlet, Marie, Krack, Paul, Pelissier, Pierre, Morand, Dominique, Delaigue, Christine, Barun, Nadia, Anheim, Mathieu, Pleuvret, Marie, Destée, Alain, Defebvre, Luc, Moreau, Caroline, Simonin, Clémence, Ryckewaert, Gilles, Kreisler, Alexandre, Mutez, Eugénie, Carrière, Nicolas, Hopes, Lucie, Tard, Céline, Grolez, Guillaume, Dujardin, Kathy, Pecheux, Nathalie, Delliaux, Marie, Rolland, Anne-Sophie, Broussolle, Emmanuel, Laurencin, Chloè, Tison, François, Burbaud, Pierre, Mangone, Graziella, Bekadar, Samir, Cormier-Dequaire, Florence, Tahiri, Khadija, Welaratne, Arlette, Czernecki, Virginie, Pineau, Fanny, Karachi, Carine, Castrioto, Anna, Durif, Frank, Tranchant, Christine, Devos, David, Thobois, Stéphane, Meissner, Wassilios G, Navarro, Maria Soledad, Cornu, Philippe, Lesage, Suzanne, Brice, Alexis, Welter, Marie Laure, and Corvol, Jean-Christophe

Published
2020
Full Text
View/download PDF

7. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial

Author

Negovanska, Velina, Welter, Marie-Laure, Corvol, Jean-Christophe, Agid, Yves, Navarro, Soledad, Meier, Niklaus, Hartmann, Andreas, Hesekamp, Helke, Cornu, Philippe, Möller, Bettina, Nebel, Adelheid, Raethjen, Jan, Knudsen, Karina, Volkmann, Jens, Falk, Daniela, Paschen, Steffen, Meister, Ingo, Kuhn, Jens, Donner, Kerstin, Kessler, Josef, Barbe, Michael, Fink, Gereon, Maarouf, Mohammad, Kühn, Andrea, Müller, Bianca, Faust, Katharina, Gruber, Doreen, Schneider, Gerd-H., Seigneuret, Eric, Pollak, Pierre, Fraix, Valerie, Kistner, Andrea, Rascol, Olivier, Arbus, Christophe, Danet, Lola, Chaynes, Patrick, Groiss, Stefan J., Hartmann, Christian, Südmeyer, Martin, Partowinia-Peters, Mahnaz, Vesper, Jan, Ledily, Severine, Damier, Philippe, Raoul, Sylvie, Trenkwalder, Claudia, Richter-Dreske, Wenke, Wächter, Tobias, Weiss, Daniel, Eusebio, Alexandro, Azulay, Jean Philippe, Polo, Gustavo, Pinto, Serge, Levin, Johannes, Dornier, Stephanie, Pene, Fredy, Hourton, Delphine, Quintin, Mathieu, Hoffart-Jourdain, Cecile, Brocvielle, Helene, Balthasar, Kerstin, Stein, Meryem, Harnisch, Susanne, Reuss, Alexander, Aminossadati, Behnaz, Nasemann, Christian, Oertel, Wolfgang, Bataille, Benoit, Hellwig, Dieter, Gharabaghi, Alireza, Amtage, Florian, Mertens, Patrick, Kloss, Manja, Post, Bart, Speelman, Hans, Lhommée, Eugénie, Wojtecki, Lars, Czernecki, Virginie, Witt, Karsten, Maier, Franziska, Tonder, Lisa, Timmermann, Lars, Hälbig, Thomas D, Pineau, Fanny, Durif, Franck, Witjas, Tatiana, Pinsker, Marcus, Mehdorn, Maximilian, Sixel-Döring, Friederike, Kupsch, Andreas, Krüger, Rejko, Elben, Saskia, Chabardès, Stephan, Thobois, Stéphane, Brefel-Courbon, Christine, Ory-Magne, Fabienne, Regis, Jean-Marie, Maltête, David, Sauvaget, Anne, Rau, Jörn, Schnitzler, Alfons, Schüpbach, Michael, Schade-Brittinger, Carmen, Deuschl, Gunther, Houeto, Jean-Luc, and Krack, Paul

Published
2018
Full Text
View/download PDF

8. Prospective acceptability of digital therapy for major depressive disorder in France: multicentric real-life study. (Preprint)

Author

Amiot, Odile, primary, Sauvaget, Anne, additional, Alamome, Isabelle, additional, Bulteau, Samuel, additional, Charpeaud, Thomas, additional, Clair, Anne-Hélène, additional, Courtet, Philippe, additional, Drapier, Dominique, additional, Haffen, Emmanuel, additional, Fakra, Eric, additional, Christian, Gaudeau-Bosma, additional, Gourion-Gaillard, Adeline, additional, Mouchabac, Stéphane, additional, Pineau, Fanny, additional, Narboni, Véronique, additional, Duburcq, Anne, additional, and Lecardeur, Laurent, additional

Published
2023
Full Text
View/download PDF

10. Quality of life predicts outcome of deep brain stimulation in early Parkinson disease

Author

Schuepbach, W.M. Michael, Tonder, Lisa, Schnitzler, Alfons, Krack, Paul, Rau, Joern, Hartmann, Andreas, Hälbig, Thomas, Pineau, Fanny, Falk, Andrea, Paschen, Laura, Paschen, Stephen, Volkmann, Jens, Dafsari, Haidar S., Barbe, Michael T., Fink, Gereon R., Kühn, Andrea, Kupsch, Andreas, Schneider, Gerd-H., Seigneuret, Eric, Fraix, Valerie, Kistner, Andrea, Chaynes, P. Patrick, Ory-Magne, Fabienne, Brefel-Courbon, Christine, Vesper, Jan, Wojtecki, Lars, Derrey, Stéphane, Maltête, David, Damier, Philippe, Derkinderen, Pascal, Sixel-Döring, Friederike, Trenkwalder, Claudia, Gharabaghi, Alireza, Wächter, Tobias, Weiss, Daniel, Pinsker, Marcus O., Regis, Jean-Marie, Witjas, Tatiana, Thobois, Stephane, Mertens, Patrick, Knudsen, Karina, Schade-Brittinger, Carmen, Houeto, Jean-Luc, Agid, Yves, Vidailhet, Marie, Timmermann, Lars, and Deuschl, Günther

Published
2019
Full Text
View/download PDF

11. Behavioural disinhibition in frontotemporal dementia investigated within an ecological framework

Author

Tanguy, Delphine, primary, Rametti-Lacroux, Armelle, additional, Bouzigues, Arabella, additional, Saracino, Dario, additional, Le Ber, Isabelle, additional, Godefroy, Valérie, additional, Morandi, Xavier, additional, Jannin, Pierre, additional, Levy, Richard, additional, Batrancourt, Bénédicte, additional, Migliaccio, Raffaella, additional, Azuar, Carole, additional, Dubois, Bruno, additional, Lecouturier, Karen, additional, Araujo, Carla M., additional, Janvier, Estelle, additional, Jourdain, Aline, additional, Coriou, Sophie, additional, Brochard, Vanessa B., additional, Gaudebout, Cécile, additional, Ferrand-Verdejo, Johan, additional, Bonnefous, Louis, additional, Pochan-Leva, Flore, additional, Jeanne, Lucie, additional, Joulié, Mathilde, additional, Provost, Myriam, additional, Renaud, Rozenn, additional, Hachemi, Sarah, additional, Guillemot, Vincent, additional, Bendetowicz, David, additional, Carle, Guilhem, additional, Socha, Julie, additional, Pineau, Fanny, additional, Marin, Frédéric, additional, Liu, Yongjian, additional, Mullot, Pierre, additional, Mousli, Aymen, additional, Blossier, Armelle, additional, Visentin, Giulia, additional, Tanguy, Delphine, additional, Sezer, Idil, additional, Boucly, Mathilde, additional, Cabrol-Douat, Blandine, additional, Odobez, Raphaëlle, additional, Marque, Constance, additional, Tessereau-Barbot, Daphné, additional, Raud, Anaïs, additional, Funkiewiez, Aurélie, additional, Chamayou, Céline, additional, Cognat, Emmanuel, additional, Le Bozec, Manon, additional, Le Du, Vincent, additional, Bombois, Stéphanie, additional, Simard, Camille, additional, Fulcheri, Paolo, additional, Guitton, Hortense, additional, Peltier, Caroline, additional, Lejeune, François-Xavier, additional, Jorgensen, Lars, additional, Mariani, Louise-Laure, additional, Corvol, Jean-Christophe, additional, Valero-Cabre, Antoni, additional, Garcin, Béatrice, additional, and Volle, Emmanuelle, additional

Published
2023
Full Text
View/download PDF

12. Brain Dysfunction in Gait Disorders of Caribbean Atypical Parkinsonism and Progressive Supranuclear Palsy Patients: A Comparative Study

Author

Welter, Marie-Laure, primary, Vasseur, Alexandre, additional, Edragas, Regine, additional, Chaumont, Hugo, additional, Pineau, Fanny, additional, Mangone, Graziella, additional, Olivier, Claire, additional, Leber, Isabelle, additional, Rivaud-Pechoux, Sophie, additional, Lehericy, Stéphane, additional, Gallea, Cécile, additional, Yahia-Cherif, Lydia, additional, and Lannuzel, Annie, additional

Published
2023
Full Text
View/download PDF

13. Brain dysfunction in gait disorders of Caribbean Atypical Parkinsonism and Progressive Supranuclear Palsy patients: a comparative study

Author

Welter, Marie-Laure, primary, Vasseur, Alexandre, additional, Edragas, Regine, additional, Chaumont, Hugo, additional, Pineau, Fanny, additional, Mangone, Graziella, additional, Olivier, Claire, additional, Leber, Isabelle, additional, Rivaud-Pechoux, Sophie, additional, Lehericy, Stéphane, additional, Gallea, Cecile, additional, Yahia, Lydia, additional, and Lannuzel, Annie, additional

Published
2022
Full Text
View/download PDF

16. COVID-19 Presentation and Outcomes among Cancer Patients: A Matched Case-Control Study

Author

Péron, Julien, Dagonneau, Tristan, Conrad, Anne, Pineau, Fanny, Calattini, Sara, Freyer, Gilles, Perol, David, Sajous, Christophe, and Heiblig, Maël

Subjects
matched cohort study, COVID-19, cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, prognosis, mortality, Article, RC254-282
Abstract

Simple Summary Cancer patients have been described in previous studies as having a higher risk of contracting COVID-19 and a higher risk of developing a severe form of the disease. In this study, we compared a group of patients hospitalized for COVID-19 within the Lyon area with a matched group of patients free of cancer and also hospitalized for COVID-19. Cancer patients and control patients were matched in order to have a similar age, gender, and other preexisting conditions. In this study, the risk of death was higher among cancer patients, but the intensity of care was lower (lower access to intensive care unit, shorter length of stay). The risk of death among cancer patients appears to be mainly driven by the severity of the infection and therapeutic limitations decided at admission. Abstract It has been suggested that cancer patients are at higher risk of contracting COVID-19 and at higher risk of developing a severe form of the disease and fatality. This study’s objectives were to measure the excess risk of mortality and morbidity of patients with cancer among patients hospitalized for a SARS-CoV-2 infection, and to identify factors associated with the risk of death and morbidity among cancer patients. All first cancer patients hospitalized for COVID-19 in the two main hospitals of the Lyon area were included. These patients were matched based on age, gender, and comorbidities with non-cancer control patients. A total of 108 cancer patients and 193 control patients were included. The severity at admission and the symptoms were similar between the two groups. The risk of early death was higher among cancer patients, while the risk of intubation, number of days with oxygen, length of stay in ICU, and length of hospital stay were reduced. The main factors associated with early death among cancer patients was the severity of COVID-19 and the number of previous chemotherapy lines. The outcomes appear to be driven by the severity of the infection and therapeutic limitations decided at admission.

Published
2021

17. Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study

Author

Corvol, Jean-Christophe, Elbaz, Alexis, Vidailhet, Marie, Brice, Alexis, Artaud, Fanny, Bourdain, Frédéric, Brandel, Jean-Philippe, Derkinderen, Pascal, Durif, Franck, Levy, Richard, Pico, Fernando, Rascol, Olivier, Bonnet, Anne-Marie, Bonnet, Cecilia, Brefel-Courbon, Christine, Cormier-Dequaire, Florence, Degos, Bertrand, Debilly, Bérangère, Galitsky, Monique, Grabli, David, Hartmann, Andreas, Klebe, Stephan, Kraemmer, Julia, Lacomblez, Lucette, Leder, Sara, Mangone, Graziella, Mariani, Louise-Laure, Marques, Ana-Raquel, Mesnage, Valérie, Muellner, Julia, Ory-Magne, Fabienne, Planté-Bordeneuve, Violaine, Roze, Emmanuel, Tir, Melissa, You, Hana, Benchetrit, Eve, Socha, Julie, Pineau, Fanny, Vidal, Tiphaine, Pomies, Elsa, Bayet, Virginie, Lesage, Suzanne, Tahiri, Khadija, Bertrand, Hélène, Mallet, Alain, Villeret, Coralie, Mazmanian, Merry, Manseur, Hakima, Hajji, Mostafa, Le Toullec, Benjamin, Brochard, Vanessa, Roy, Monica, Rieu, Isabelle, Bernard, Stéphane, Faurie-Grepon, Antoine, Ihle, J., Artaud, F., Bekadar, S., Mangone, G., Sambin, S., Mariani, LL, Bertrand, H., Rascol, O., Durif, F., Derkinderen, P., Scherzer, C., Elbaz, A., and Corvol, JC

Published
2020
Full Text
View/download PDF

18. Blood co-expression modules identify potential modifier genes of diabetes and lung function in cystic fibrosis

Author

Pineau, Fanny, Caimmi, Davide, Magalhães, Milena, Fremy, Enora, Mohamed, Abdillah, Mely, Laurent, Leroy, Sylvie, Murris, Marlene, Claustres, Mireille, Chiron, Raphaël, De Sario, Albertina, Laboratoire de génétique des maladies rares. Pathologie moleculaire, etudes fonctionnelles et banque de données génétiques (LGMR), Université Montpellier 1 (UM1)-IFR3, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centres de Ressources et de Compétences de la Mucoviscidose [Montpellier] (CRCM [Montpellier]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve-Service des Maladies Respiratoires, Centre de Ressources et de Compétences en Mucoviscidose [Lyon] (CRCM [Lyon]), Hospices Civils de Lyon (HCL)-CHU Lyon-Hôpital Renée Sabran [CHU - HCL], Hospices Civils de Lyon (HCL), Centre de Ressources et de Compétences en Mucoviscidose [Nice] (CRCM [Nice]), Les Hôpitaux Pédiatriques de Nice CHU-Lenval, Centre de Ressources et de Compétences en Mucoviscidose [Toulouse] (CRCM [Toulouse]), CHU Toulouse [Toulouse]-Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), DE SARIO, Albertina, Centre de Ressources et de Compétences en Mucoviscidose [CHU Toulouse] (CRCM Toulouse), Service Pneumologie et allergologie pédiatrique [CHU Toulouse], Pôle Enfants [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Enfants [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

Subjects
Male, Cystic Fibrosis, Pulmonology, [SDV]Life Sciences [q-bio], Cystic Fibrosis Transmembrane Conductance Regulator, Pulmonary Function, Gene Expression, Comorbidity, Pathology and Laboratory Medicine, White Blood Cells, Endocrinology, Animal Cells, Medicine and Health Sciences, Lung, Gene Ontologies, Pseudomonas Aeruginosa, Genomics, Bacterial Pathogens, [SDV] Life Sciences [q-bio], Genetic Diseases, Medical Microbiology, Medicine, Female, Pathogens, Cellular Types, Research Article, Adult, Cell Binding, Cell Physiology, Endocrine Disorders, Science, Immune Cells, Immunology, [SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics, Microbiology, Autosomal Recessive Diseases, Pseudomonas, Diabetes Mellitus, Genetics, Humans, Pseudomonas Infections, Microbial Pathogens, Clinical Genetics, Genes, Modifier, Blood Cells, Bacteria, Organisms, Biology and Life Sciences, Computational Biology, Cell Biology, Genome Analysis, Fibrosis, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Metabolic Disorders, Mutation, Transcriptome, Developmental Biology
Abstract

International audience; Cystic fibrosis (CF) is a rare genetic disease that affects the respiratory and digestive systems. Lung disease is variable among CF patients and associated with the development of comorbidities and chronic infections. The rate of lung function deterioration depends not only on the type of mutations in CFTR, the disease-causing gene, but also on modifier genes. In the present study, we aimed to identify genes and pathways that (i) contribute to the pathogenesis of cystic fibrosis and (ii) modulate the associated comorbidities. We profiled blood samples in CF patients and healthy controls and analyzed RNA-seq data with Weighted Gene Correlation Network Analysis (WGCNA). Interestingly, lung function, body mass index, the presence of diabetes, and chronic P. aeruginosa infections correlated with four modules of co-expressed genes. Detailed inspection of networks and hub genes pointed to cell adhesion, leukocyte trafficking and production of reactive oxygen species as central mechanisms in lung function decline and cystic fibrosis-related diabetes. Of note, we showed that blood is an informative surrogate tissue to study the contribution of inflammation to lung disease and diabetes in CF patients. Finally, we provided evidence that WGCNA is useful to analyze-omic datasets in rare genetic diseases as patient cohorts are inevitably small.

Published
2020
Full Text
View/download PDF

19. DNA Methylation at ATP11A cg11702988 Is a Biomarker of Lung Disease Severity in Cystic Fibrosis: A Longitudinal Study

Author

Pineau, Fanny, primary, Caimmi, Davide, additional, Taviaux, Sylvie, additional, Reveil, Maurane, additional, Brosseau, Laura, additional, Rivals, Isabelle, additional, Drevait, Margot, additional, Vachier, Isabelle, additional, Claustres, Mireille, additional, Chiron, Raphaël, additional, and De Sario, Albertina, additional

Published
2021
Full Text
View/download PDF

21. Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations

Author

Mangone, Graziella, primary, Bekadar, Samir, additional, Cormier-Dequaire, Florence, additional, Tahiri, Khadija, additional, Welaratne, Arlette, additional, Czernecki, Virginie, additional, Pineau, Fanny, additional, Karachi, Carine, additional, Castrioto, Anna, additional, Durif, Frank, additional, Tranchant, Christine, additional, Devos, David, additional, Thobois, Stéphane, additional, Meissner, Wassilios G, additional, Navarro, Maria Soledad, additional, Cornu, Philippe, additional, Lesage, Suzanne, additional, Brice, Alexis, additional, Welter, Marie Laure, additional, Corvol, Jean-Christophe, additional, Benchetrit, Eve, additional, Delaby, Laure, additional, Berthet, Deborah, additional, Danjou, Fabrice, additional, Vidaihlet, Marie, additional, Krack, Paul, additional, Pelissier, Pierre, additional, Morand, Dominique, additional, Delaigue, Christine, additional, Barun, Nadia, additional, Anheim, Mathieu, additional, Pleuvret, Marie, additional, Destée, Alain, additional, Defebvre, Luc, additional, Moreau, Caroline, additional, Simonin, Clémence, additional, Ryckewaert, Gilles, additional, Kreisler, Alexandre, additional, Mutez, Eugénie, additional, Carrière, Nicolas, additional, Hopes, Lucie, additional, Tard, Céline, additional, Grolez, Guillaume, additional, Dujardin, Kathy, additional, Pecheux, Nathalie, additional, Delliaux, Marie, additional, Rolland, Anne-Sophie, additional, Broussolle, Emmanuel, additional, Laurencin, Chloè, additional, Tison, François, additional, and Burbaud, Pierre, additional

Published
2020
Full Text
View/download PDF

22. Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study

Author

Ihle, J., primary, Artaud, F., additional, Bekadar, S., additional, Mangone, G., additional, Sambin, S., additional, Mariani, LL, additional, Bertrand, H., additional, Rascol, O., additional, Durif, F., additional, Derkinderen, P., additional, Scherzer, C., additional, Elbaz, A., additional, Corvol, JC, additional, Corvol, Jean-Christophe, additional, Elbaz, Alexis, additional, Vidailhet, Marie, additional, Brice, Alexis, additional, Artaud, Fanny, additional, Bourdain, Frédéric, additional, Brandel, Jean-Philippe, additional, Derkinderen, Pascal, additional, Durif, Franck, additional, Levy, Richard, additional, Pico, Fernando, additional, Rascol, Olivier, additional, Bonnet, Anne-Marie, additional, Bonnet, Cecilia, additional, Brefel-Courbon, Christine, additional, Cormier-Dequaire, Florence, additional, Degos, Bertrand, additional, Debilly, Bérangère, additional, Galitsky, Monique, additional, Grabli, David, additional, Hartmann, Andreas, additional, Klebe, Stephan, additional, Kraemmer, Julia, additional, Lacomblez, Lucette, additional, Leder, Sara, additional, Mangone, Graziella, additional, Mariani, Louise-Laure, additional, Marques, Ana-Raquel, additional, Mesnage, Valérie, additional, Muellner, Julia, additional, Ory-Magne, Fabienne, additional, Planté-Bordeneuve, Violaine, additional, Roze, Emmanuel, additional, Tir, Melissa, additional, You, Hana, additional, Benchetrit, Eve, additional, Socha, Julie, additional, Pineau, Fanny, additional, Vidal, Tiphaine, additional, Pomies, Elsa, additional, Bayet, Virginie, additional, Lesage, Suzanne, additional, Tahiri, Khadija, additional, Bertrand, Hélène, additional, Mallet, Alain, additional, Villeret, Coralie, additional, Mazmanian, Merry, additional, Manseur, Hakima, additional, Hajji, Mostafa, additional, Le Toullec, Benjamin, additional, Brochard, Vanessa, additional, Roy, Monica, additional, Rieu, Isabelle, additional, Bernard, Stéphane, additional, and Faurie-Grepon, Antoine, additional

Published
2020
Full Text
View/download PDF

24. Reducing Attentional Bias in Individuals With Alcohol Use Disorders With a Tablet Application: A Randomized Controlled Trial Pilot Study

Author

Pereira, Bruno, Benchetrit, Eve, Socha, Julie, Pineau, Fanny, Elbaz, Alexis, Artaud, Fanny, Mangone, Graziella, You, Hana, Cormier, Florence, Galitstky, Monique, Pomies, Elsa, Derkinderen, Pascal, Weintraub, Daniel, Corvol, Jean Christophe, Chereau-Boudet, Isabelle, Fantini, Maria Livia, Marques, Ana, Derost, Philippe, Boirie, Yves, Girard, Romuald, Obeso, Ignacio, Thobois, Stéphane, Park, Seongmin, Vidal, Tiphaine, Favre, Emilie, Ulla, Miguel, Broussolle, Emmanuel, Krack, Paul, Dreher, Jean-Claude, Corvol, Jean-Christophe, Durif, Franck, Meissner, Wassilios, Azulay, Jean-Philippe, Haddad, Raphaël, Guimarães-Costa, Raquel, Mariani, Louise-Laure, Cormier-Dequaire, Florence, Thalamas, Claire, Galitzky, Monique, Boraud, Thomas, Debilly, Bérengère, Eusebio, Alexandre, Houot, Marion, Dellapina, Estelle, Chaigneau, Véronique, Salis, Alexandrine, Lacomblez, Lucette, Benel, Laurent, Rascol, Olivier, Flaudias, Valentin, Zerhouni, Oulmann, Chakroun-Baggioni, Nadia, Pires, Sylvie, Schmitt, Audrey, De Chazeron, Ingrid, Llorca, Pierre Michel, Brousse, Georges, Service de Psychiatrie de l'Adulte B [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Laboratoire Parisien de Psychologie Sociale (LAPPS), Université Paris Nanterre (UPN)-Université Paris 8 Vincennes-Saint-Denis (UP8), Laboratoire de Psychologie Sociale et Cognitive (LAPSCO), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), service de Biostatistiques, DRCI, Centre Hospitalier Universitaire de Clermont-Ferrand, Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique (CNRS), Epidemiology, Departments of Health Sciences Research, Mayo Clinic College of Medicine, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Neuropathies du système nerveux entérique et pathologies digestives, implication des cellules gliales entériques, Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Neurology, University of Pennsylvania [Philadelphia], Centres d'addictologies - Région Centre, CHU Clermont-Ferrand, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Service de neurologie, Hôpital Gabriel Montpied, Unité de Nutrition Humaine (UNH), Institut National de la Recherche Agronomique (INRA)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université, Institut des sciences cognitives Marc Jeannerod - Centre de neuroscience cognitive - UMR5229 (CNC), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie, Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de Neurologie [CHU Clermont-Ferrand], Hospices Civils de Lyon (HCL), Neurosciences précliniques, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Neurodégénératives [Bordeaux] (IMN), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Myologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de neurologie [Le Kremlin Bicêtre], Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre, CIC - Biotherapie - Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Toulouse, Laboratoire Mouvement Adaptation Cognition (MAC), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Institut de Neurosciences de la Timone (INT), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Imagerie Biomédicale (LIB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Imagerie cérébrale et handicaps neurologiques, Institut des sciences du cerveau de Toulouse. (ISCT), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UPS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UPS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Inter-universitaire de Psychologie : Personnalité, Cognition, Changement Social (LIP-PC2S ), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Grenoble Alpes (UGA), Laboratoire de Psychologie Sociale et Cognitive - Clermont Auvergne (LAPSCO), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), and Université Paris 8 Vincennes-Saint-Denis (UP8)-Université Paris Nanterre (UPN)

Subjects
Adult, Male, Cognitive bias modification, Ecological validity, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Mental processes, education, Craving, Pilot Projects, Alcohol use disorder, Attentional bias, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Memory, medicine, Humans, ComputingMilieux_MISCELLANEOUS, Tablet dosage form, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Cognitive Behavioral Therapy, Ethanol, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Play behavior, Cognition, General Medicine, Middle Aged, medicine.disease, Cognitive bias, 030227 psychiatry, Alcoholism, Inhibition, Psychological, Treatment Outcome, Therapy, Computer-Assisted, [SCCO.PSYC]Cognitive science/Psychology, Female, medicine.symptom, business, 030217 neurology & neurosurgery, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Clinical psychology
Abstract

Aims Cognitive bias modification (CBM) training has been considered a promising and effective intervention tool for reducing cognitive biases toward alcohol. However, the link between the cognitive process and actual behavior remains statistically insignificant because computerized tasks do not have sufficient ecological validity and suffer from high dropout rates. The recent development of ‘serious games’ has shown encouraging results in maintaining adherence to health-related interventions. We aim to evaluate a CBM program using a gamified attentional bias (AB) training procedure on a touchpad for individuals with alcohol use disorders. Methods Forty-one patients were included in this study, 33 of whom displayed an AB and were randomly assigned into the ‘CBM group’ (N = 18, 16.7% women) or ‘Memory group’—which involved playing a memory game—(N = 15, no woman). Eight other participants (12.5% women) with no AB comprised the ‘Without AB group’. Efficacy was assessed for AB, craving, and inhibition and attentional capacities before and after the program. Results We observed that the reduction of AB was higher for the ‘CBM group’ (Mbefore = 153.61, SD = 172.21; Mafter = 18.00, SD = 77.71; t (17) = 4.21, P = 0.001) than for the ‘Memory group’ (Mbefore = 73.20, SD = 66.65; Mafter =42.47, SD = 113.77; ts Conclusions This study demonstrated an increased reduction of AB for patients included in the CBM program on a touchpad than for patients playing only a memory game.

Published
2020
Full Text
View/download PDF

25. Glucocorticoid receptors signaling impairment potentiates amyloid‐β oligomers‐induced pathology in an acute model of Alzheimer’s disease

Author

Canet, Geoffrey, primary, Pineau, Fanny, additional, Zussy, Charleine, additional, Hernandez, Célia, additional, Hunt, Hazel, additional, Chevallier, Nathalie, additional, Perrier, Véronique, additional, Torrent, Joan, additional, Belanoff, Joseph K., additional, Meijer, Onno C., additional, Desrumaux, Catherine, additional, and Givalois, Laurent, additional

Published
2019
Full Text
View/download PDF

26. Quality of life predicts outcome of deep brain stimulation in early Parkinson disease

Author

Schuepbach, W. M. Michael, Tonder, Lisa, Schnitzler, Alfons, Krack, Paul, Rau, Joern, Hartmann, Andreas, Haelbig, Thomas D., Pineau, Fanny, Falk, Andrea, Paschen, Laura, Paschen, Stephen, Volkmann, Jens, Dafsari, Haidar S., Barbe, Michael T., Fink, Gereon R., Kuehn, Andrea, Kupsch, Andreas, Schneider, Gerd-H, Seigneuret, Eric, Fraix, Valerie, Kistner, Andrea, Chaynes, P. Patrick, Ory-Magne, Fabienne, Brefel-Courbon, Christine, Vesper, Jan, Wojtecki, Lars, Derrey, Stephane, Maltete, David, Damier, Philippe, Derkinderen, Pascal, Sixel-Doering, Friederike, Trenkwalder, Claudia, Gharabaghi, Alireza, Waechter, Tobias, Weiss, Daniel, Pinsker, Marcus O., Regis, Jean-Marie, Witjas, Tatiana, Thobois, Stephane, Mertens, Patrick, Knudsen, Karina, Schade-Brittinger, Carmen, Houeto, Jean-Luc, Agid, Yves, Vidailhet, Marie, Timmermann, Lars, Deuschl, Guenther, Schuepbach, W. M. Michael, Tonder, Lisa, Schnitzler, Alfons, Krack, Paul, Rau, Joern, Hartmann, Andreas, Haelbig, Thomas D., Pineau, Fanny, Falk, Andrea, Paschen, Laura, Paschen, Stephen, Volkmann, Jens, Dafsari, Haidar S., Barbe, Michael T., Fink, Gereon R., Kuehn, Andrea, Kupsch, Andreas, Schneider, Gerd-H, Seigneuret, Eric, Fraix, Valerie, Kistner, Andrea, Chaynes, P. Patrick, Ory-Magne, Fabienne, Brefel-Courbon, Christine, Vesper, Jan, Wojtecki, Lars, Derrey, Stephane, Maltete, David, Damier, Philippe, Derkinderen, Pascal, Sixel-Doering, Friederike, Trenkwalder, Claudia, Gharabaghi, Alireza, Waechter, Tobias, Weiss, Daniel, Pinsker, Marcus O., Regis, Jean-Marie, Witjas, Tatiana, Thobois, Stephane, Mertens, Patrick, Knudsen, Karina, Schade-Brittinger, Carmen, Houeto, Jean-Luc, Agid, Yves, Vidailhet, Marie, Timmermann, Lars, and Deuschl, Guenther

Abstract

Objective To investigate predictors for improvement of disease-specific quality of life (QOL) after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications. Methods We performed a secondary analysis of data from the previously published EARLYSTIM study, a prospective randomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-up with disease-specific QOL (39-item Parkinson's Disease Questionnaire summary index [PDQ-39-SI]) as the primary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration of motor complications, and disease severity measured at baseline with the Unified Parkinson's Disease Rating Scale (UPDRS) (UPDRS-III off and on medications, UPDRS-IV) were conducted to determine predictors of change in PDQ-39-SI. Results PDQ-39-SI at baseline was correlated to the change in PDQ-39-SI after 24 months in both treatment groups (p < 0.05). The higher the baseline score (worse QOL) the larger the improvement in QOL after 24 months. No correlation was found for any of the other baseline characteristics analyzed in either treatment group. Conclusion Impaired QOL as subjectively evaluated by the patient is the most important predictor of benefit in patients with PD and early motor complications, fulfilling objective gold standard inclusion criteria for STN-DBS. Our results prompt systematically including evaluation of disease-specific QOL when selecting patients with PD for STN-DBS. Clinicaltrials.gov identifier NCT00354133.

Published
2019

27. Programming parameters of subthalamic deep brain stimulators in Parkinson's disease from a controlled trial

Author

Knudsen, K., Krack, P., Tonder, L., Houeto, J. -L., Rau, J., Schade-Brittinger, C., Hartmann, A., Haelbig, Thomas D., Paschen, Stephen, Barbe, Michael T., Kuehn, Andrea, Fraix, Valerie, Brefel-Courbon, Christine, Vesper, Jan, Maltete, David, Sixel-Doering, Friederike, Weiss, Daniel, Witjas, Tatiana, Thobois, Stephane, Agid, Yves, Schnitzler, A., Schuepbach, W. M. M., Timmermann, L., Damier, Philippe, Vidailhet, M., Deuschl, G., Czernecki, Virginie, Hesekamp, Helke, Meier, Nildaus, Negovanska, Velina, Welter, Marie-Laure, Corvol, Jean-Christophe, Pineau, Fanny, Cornu, Philippe, Navarro, Soledad, Paschen, Laura, Volkmann, Jens, Moeller, Bettina, Nebel, Adelheid, Witt, Karsten, Raethjen, Jan, Falk, Daniels, Mehdorn, Maktnilian, Meister, Ingo G., Kuhn, Jens, Dafsari, Haidar S., Fink, Gereon, Donner, Kerstin, Kessler, Josef, Maarouf, Mohammad, Kupsch, Andeas, Schneider, Gerd -H., Gruber, Doreen, Mueller, Bianca, Faust, Katharina, Chabardes, Stephan, Kistler, Andrea, Pollak, Pierre, Ory-Magne, Fabienne, Rascol, Oliver, Arbus, Christophe, Chaynes, P. Patrick, Danet, Lola, Derrey, Stephane, Lefaucheur, Romain, Benatru, Isabelle, Bataille, Benoit, Colin, Olivier, Wojtecki, Lars, Groiss, Stefan J., Elben, Saskia, Hartmann, Christian, Suedmeyer, Martin, Pinsker, Marcus O., Amtage, Florian, Gharabaghi, Alireza, Waechter, Tobias, Kruger, Rejko, Derkinderen, Pascal, Ledily, Severine, Raoul, Sylvia, Sauvaget, Anne, Elena-Klinik, Paracelsus, Trenkwalder, Claudia, Richter-Dreske, Wenke, Regis, Jean-Marie, Eusebio, Alexandro, Philippe, Jean, Polo, Gustavo, Pinto, Serge, Mertens, Patrick, Levin, Johannes, Oertel, Wolfgang H., Dornier, Stephanie, Pene, Fredy, Hourton, Delphine, Bissery, Anne, Bouton, Didier, Quintin, Mathieu, Hoffart-Jourdain, Cecile, Brocvielle, Helene, Partowinia-Peters, Mahnaz, Schickor, Mandy, Balthasar, Kerstin, Stein, Meryem, Harnisch, Susanne, Reuss, Alexander, Aminossadati, Behnaz, Nasemann, Christian, Stoker, Valerie, Knudsen, K., Krack, P., Tonder, L., Houeto, J. -L., Rau, J., Schade-Brittinger, C., Hartmann, A., Haelbig, Thomas D., Paschen, Stephen, Barbe, Michael T., Kuehn, Andrea, Fraix, Valerie, Brefel-Courbon, Christine, Vesper, Jan, Maltete, David, Sixel-Doering, Friederike, Weiss, Daniel, Witjas, Tatiana, Thobois, Stephane, Agid, Yves, Schnitzler, A., Schuepbach, W. M. M., Timmermann, L., Damier, Philippe, Vidailhet, M., Deuschl, G., Czernecki, Virginie, Hesekamp, Helke, Meier, Nildaus, Negovanska, Velina, Welter, Marie-Laure, Corvol, Jean-Christophe, Pineau, Fanny, Cornu, Philippe, Navarro, Soledad, Paschen, Laura, Volkmann, Jens, Moeller, Bettina, Nebel, Adelheid, Witt, Karsten, Raethjen, Jan, Falk, Daniels, Mehdorn, Maktnilian, Meister, Ingo G., Kuhn, Jens, Dafsari, Haidar S., Fink, Gereon, Donner, Kerstin, Kessler, Josef, Maarouf, Mohammad, Kupsch, Andeas, Schneider, Gerd -H., Gruber, Doreen, Mueller, Bianca, Faust, Katharina, Chabardes, Stephan, Kistler, Andrea, Pollak, Pierre, Ory-Magne, Fabienne, Rascol, Oliver, Arbus, Christophe, Chaynes, P. Patrick, Danet, Lola, Derrey, Stephane, Lefaucheur, Romain, Benatru, Isabelle, Bataille, Benoit, Colin, Olivier, Wojtecki, Lars, Groiss, Stefan J., Elben, Saskia, Hartmann, Christian, Suedmeyer, Martin, Pinsker, Marcus O., Amtage, Florian, Gharabaghi, Alireza, Waechter, Tobias, Kruger, Rejko, Derkinderen, Pascal, Ledily, Severine, Raoul, Sylvia, Sauvaget, Anne, Elena-Klinik, Paracelsus, Trenkwalder, Claudia, Richter-Dreske, Wenke, Regis, Jean-Marie, Eusebio, Alexandro, Philippe, Jean, Polo, Gustavo, Pinto, Serge, Mertens, Patrick, Levin, Johannes, Oertel, Wolfgang H., Dornier, Stephanie, Pene, Fredy, Hourton, Delphine, Bissery, Anne, Bouton, Didier, Quintin, Mathieu, Hoffart-Jourdain, Cecile, Brocvielle, Helene, Partowinia-Peters, Mahnaz, Schickor, Mandy, Balthasar, Kerstin, Stein, Meryem, Harnisch, Susanne, Reuss, Alexander, Aminossadati, Behnaz, Nasemann, Christian, and Stoker, Valerie

Abstract

Background: Programming algorithms have never been tested for outcome. The EARLYSTIM study showed superior outcomes of deep brain stimulation of the subthalamic nucleus (STN-DBS) over best medical treatment in early Parkinson's disease (PD). Patients were programmed according to common guidelines but customized for each patient. Methods: Stimulation parameters were systematically documented at 1, 5, 12, and 24 month in the cohort of 114 patients who had bilateral STN-DBS at 24 month. We investigated the influence of atypical programming, changes of stimulated electrode contacts and stimulation energy delivered. Outcomes were the Unified Parkinson's Disease Rating Scale (UPDRS) motor and ADL-subscores, health-related quality of life (PDQ-39) summary index and mobility- and ADL-subscores. Results: At 1/5/12/24 months follow up, mean amplitude (1.8/2.5/2.6/2.8 V), impedance (1107/1286/1229/1189 Omega) and TEED (33.7/69.0/84.4/93.0 V2*mu s*Hz/Omega) mainly increased in the first 5 months, while mean pulse width (60.0/62.5/65.1/65.8 mu s), frequency (130/137.7/139.1/142.7 Hz) remained relatively stable. Typical programming (single monopolar electrode contact) was used in 80.7% of electrodes. Double monopolar (11/114) and bipolar (2/114) stimulation was only rarely required. There was no significant difference in clinical outcomes between the patient groups requiring contact changes (n = 32/28.1%) nor between (n = 83/72.8%) versus non-typical programming. Energy used for STN-DBS was higher for the dominant side of PD. Conclusion: In the first 5 months an increase in amplitude is required to compensate for various factors. Monopolar stimulation is sufficient in 80% of patients at 24 months. Homogeneous stimulation strategies can account for the favorable outcomes reported in the Earlystim study.

Published
2019

29. Dynamic changes of DNA methylation and lung disease in cystic fibrosis: lessons from a monogenic disease

Author

Magalhães, Milena, primary, Tost, Jörg, additional, Pineau, Fanny, additional, Rivals, Isabelle, additional, Busato, Florence, additional, Alary, Nathan, additional, Mely, Laurent, additional, Leroy, Sylvie, additional, Murris, Marlène, additional, Caimmi, Davide, additional, Claustres, Mireille, additional, Chiron, Raphaël, additional, and De Sario, Albertina, additional

Published
2018
Full Text
View/download PDF

30. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial

Author

Lhommée, Eugénie, primary, Wojtecki, Lars, additional, Czernecki, Virginie, additional, Witt, Karsten, additional, Maier, Franziska, additional, Tonder, Lisa, additional, Timmermann, Lars, additional, Hälbig, Thomas D, additional, Pineau, Fanny, additional, Durif, Franck, additional, Witjas, Tatiana, additional, Pinsker, Marcus, additional, Mehdorn, Maximilian, additional, Sixel-Döring, Friederike, additional, Kupsch, Andreas, additional, Krüger, Rejko, additional, Elben, Saskia, additional, Chabardès, Stephan, additional, Thobois, Stéphane, additional, Brefel-Courbon, Christine, additional, Ory-Magne, Fabienne, additional, Regis, Jean-Marie, additional, Maltête, David, additional, Sauvaget, Anne, additional, Rau, Jörn, additional, Schnitzler, Alfons, additional, Schüpbach, Michael, additional, Schade-Brittinger, Carmen, additional, Deuschl, Gunther, additional, Houeto, Jean-Luc, additional, Krack, Paul, additional, Negovanska, Velina, additional, Welter, Marie-Laure, additional, Corvol, Jean-Christophe, additional, Agid, Yves, additional, Navarro, Soledad, additional, Meier, Niklaus, additional, Hartmann, Andreas, additional, Hesekamp, Helke, additional, Cornu, Philippe, additional, Möller, Bettina, additional, Nebel, Adelheid, additional, Raethjen, Jan, additional, Knudsen, Karina, additional, Volkmann, Jens, additional, Falk, Daniela, additional, Paschen, Steffen, additional, Meister, Ingo, additional, Kuhn, Jens, additional, Donner, Kerstin, additional, Kessler, Josef, additional, Barbe, Michael, additional, Fink, Gereon, additional, Maarouf, Mohammad, additional, Kühn, Andrea, additional, Müller, Bianca, additional, Faust, Katharina, additional, Gruber, Doreen, additional, Schneider, Gerd-H., additional, Seigneuret, Eric, additional, Pollak, Pierre, additional, Fraix, Valerie, additional, Kistner, Andrea, additional, Rascol, Olivier, additional, Arbus, Christophe, additional, Danet, Lola, additional, Chaynes, Patrick, additional, Groiss, Stefan J., additional, Hartmann, Christian, additional, Südmeyer, Martin, additional, Partowinia-Peters, Mahnaz, additional, Vesper, Jan, additional, Ledily, Severine, additional, Damier, Philippe, additional, Raoul, Sylvie, additional, Trenkwalder, Claudia, additional, Richter-Dreske, Wenke, additional, Wächter, Tobias, additional, Weiss, Daniel, additional, Eusebio, Alexandro, additional, Azulay, Jean Philippe, additional, Polo, Gustavo, additional, Pinto, Serge, additional, Levin, Johannes, additional, Dornier, Stephanie, additional, Pene, Fredy, additional, Hourton, Delphine, additional, Quintin, Mathieu, additional, Hoffart-Jourdain, Cecile, additional, Brocvielle, Helene, additional, Balthasar, Kerstin, additional, Stein, Meryem, additional, Harnisch, Susanne, additional, Reuss, Alexander, additional, Aminossadati, Behnaz, additional, Nasemann, Christian, additional, Oertel, Wolfgang, additional, Bataille, Benoit, additional, Hellwig, Dieter, additional, Gharabaghi, Alireza, additional, Amtage, Florian, additional, Mertens, Patrick, additional, Kloss, Manja, additional, Post, Bart, additional, and Speelman, Hans, additional

Published
2018
Full Text
View/download PDF

31. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.

Author

Lhommee, Eugenie, Wojtecki, Lars, Czernecki, Virginie, Witt, Karsten, Maier, Franziska, Tonder, Lisa, Timmermann, Lars, Halbig, Thomas D., Pineau, Fanny, Durif, Franck, Witjas, Tatiana, Pinsker, Marcus, Mehdorn, Maximilian, Sixel-Doring, Friederike, Kupsch, Andreas, Krüger, Rejko, Elben, Saskia, Chabardes, Stephan, Thobois, Stephane, Brefel-Courbon, Christine, Ory-Magne, Fabienne, Regis, Jean-Marie, Maltete, David, Sauvaget, Anne, Rau, Jorn, Schnitzler, Alfons, Schupbach, Michael, Schade-Brittinger, Carmen, Deuschl, Gunther, Houeto, Jean-Luc, Krack, Paul, Lhommee, Eugenie, Wojtecki, Lars, Czernecki, Virginie, Witt, Karsten, Maier, Franziska, Tonder, Lisa, Timmermann, Lars, Halbig, Thomas D., Pineau, Fanny, Durif, Franck, Witjas, Tatiana, Pinsker, Marcus, Mehdorn, Maximilian, Sixel-Doring, Friederike, Kupsch, Andreas, Krüger, Rejko, Elben, Saskia, Chabardes, Stephan, Thobois, Stephane, Brefel-Courbon, Christine, Ory-Magne, Fabienne, Regis, Jean-Marie, Maltete, David, Sauvaget, Anne, Rau, Jorn, Schnitzler, Alfons, Schupbach, Michael, Schade-Brittinger, Carmen, Deuschl, Gunther, Houeto, Jean-Luc, and Krack, Paul

Abstract

BACKGROUND: Although subthalamic stimulation is a recognised treatment for motor complications in Parkinson's disease, reports on behavioural outcomes are controversial, which represents a major challenge when counselling candidates for subthalamic stimulation. We aimed to assess changes in behaviour in patients with Parkinson's disease receiving combined treatment with subthalamic stimulation and medical therapy over a 2-year follow-up period as compared with the behavioural evolution under medical therapy alone. METHODS: We did a parallel, open-label study (EARLYSTIM) at 17 surgical centres in France (n=8) and Germany (n=9). We recruited patients with Parkinson's disease who were disabled by early motor complications. Participants were randomly allocated (1:1) to either medical therapy alone or bilateral subthalamic stimulation plus medical therapy. The primary outcome was mean change in quality of life from baseline to 2 years. A secondary analysis was also done to assess behavioural outcomes. We used the Ardouin Scale of Behavior in Parkinson's Disease to assess changes in behaviour between baseline and 2-year follow-up. Apathy was also measured using the Starkstein Apathy Scale, and depression was assessed with the Beck Depression Inventory. The secondary analysis was done in all patients recruited. We used a generalised estimating equations (GEE) regression model for individual items and mixed model regression for subscores of the Ardouin scale and the apathy and depression scales. This trial is registered with ClinicalTrials.gov, number NCT00354133. The primary analysis has been reported elsewhere; this report presents the secondary analysis only. FINDINGS: Between July, 2006, and November, 2009, 251 participants were recruited, of whom 127 were allocated medical therapy alone and 124 were assigned bilateral subthalamic stimulation plus medical therapy. At 2-year follow-up, the levodopa-equivalent dose was reduced by 39% (-363.3 mg/day [SE 41.8]) in individua

Published
2018
Full Text
View/download PDF

32. Glucocorticoid receptors signaling impairment potentiates amyloid‐β oligomers‐induced pathology in an acute model of Alzheimer's disease.

Author

Canet, Geoffrey, Pineau, Fanny, Zussy, Charleine, Hernandez, Célia, Hunt, Hazel, Chevallier, Nathalie, Perrier, Véronique, Torrent, Joan, Belanoff, Joseph K., Meijer, Onno C., Desrumaux, Catherine, and Givalois, Laurent

Abstract

Dysregulation of the hypothalamic‐pituitary‐adrenal (HPA) axis occurs early in Alzheimer's disease (AD), associated with elevated circulating glucocorticoids (GC) and glucocorticoid receptors (GR) signaling impairment. However, the precise role of GR in the pathophysiology of AD remains unclear. Using an acute model of AD induced by the intracerebroventricular injection of amyloid‐β oligomers (oAβ), we analyzed cellular and behavioral hallmarks of AD, GR signaling pathways, processing of amyloid precursor protein, and enzymes involved in Tau phosphorylation. We focused on the prefrontal cortex (PFC), particularly rich in GR, early altered in AD and involved in HPA axis control and cognitive functions. We found that oAβ impaired cognitive and emotional behaviors, increased plasma GC levels, synaptic deficits, apoptosis and neuroinflammatory processes. Moreover, oAβ potentiated the amyloidogenic pathway and enzymes involved both in Tau hyperphosphorylation and GR activation. Treatment with a selective GR modulator (sGRm) normalized plasma GC levels and all behavioral and biochemical parameters analyzed. GR seems to occupy a central position in the pathophysiology of AD. Deregulation of the HPA axis and a feed‐forward effect on PFC GR sensitivity could participate in the etiology of AD, in perturbing Aβ and Tau homeostasis. These results also reinforce the therapeutic potential of sGRm in AD. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

34. La educación desde los pueblos indígenas de Bolivia. Análisis del proyecto de Nueva Ley de Educación 'Avelino Siñani y Elizardo Pérez', como resistencia frente a la educación para la globalización neoliberal

Author

Gómez, Luis, Gómez, Juan, Pineau, Fanny, and Mora Ramírez, András

Abstract

En este ensayo nos interesa abordar las implicaciones del cambio político y social que se vive en América Latina, particularmente enfocado en Bolivia y sobre la educación y su relación con el desarrollo, a partir del estudio del proyecto de Nueva Ley de Educación “Avelino Siñani-Elizardo Pérez”, presentado para su tramitación al Congreso Nacional por iniciativa del Gobierno de la República y del movimiento indígena-popular. Mediante la metodología del análisis de coyuntura y del análisis estructural temático del discurso, se busca mostrar de qué manera esta reforma construye formas de resistencia cultural y alternativas educativas ante la llamada educación para la globalización neoliberal, propia de un modelo de desarrollo económico impuesto a Bolivia hace más de 20 años.AbstractThis essay aims to find out on the implications of political and social changes currently in process in Latin America focusing in Bolivia’s education and development in the New Act in Education, Avelino Siñani-Elizardo Pérez. The bill of law was submitted to the National Congress by the Government of Bolivia and the Indigenous Popular Movement. Based on current situation analysis and in topic-structure discourse analysis as a methodological approach, it discourse analysis as a methodological approach, it endeavours to show how this reform may build cultural and alternative education as ways of resistance to the socalled education for the neliberal globalization. The latter is featured in the economic development model, imposed to Bolivia 20 years ago.

Published
2010

37. La educación desde los pueblos indígenas de Bolivia. Análisis del proyecto de Nueva Ley de Educación 'Avelino Siñani y Elizardo Pérez', como resistencia frente a la educación para la globalización neoliberal

Author

Gómez Torres, Juan Rafael, Gómez Ordoñez, Luis, Pineau, Fanny, and Mora, Andrés

Subjects
Movimiento indígena popular, Bolivia, re- sistencia cultural, alternativas educativas, América Latina
Abstract

En este ensayo nos interesa abordar las implicaciones del cambio político y social que se vive en América Latina, particularmente enfocado en Bolivia y sobre la educación y su relación con el desarrollo, a partir del estudio del proyecto de Nueva Ley de Educación “Avelino Siñani-Elizardo Pérez”, presentado para su tramitación al Congreso Nacional por iniciativa del Gobierno de la República y del movimiento indígena-popular. Mediante la metodología del análisis de coyuntura y del análisis estructural temático del discurso, se busca mostrar de qué manera esta reforma construye formas de resistencia cultural y alternativas educativas ante la llamada educación para la globalización. Universidad Nacional de Costa Rica

Published
2010

38. La (re)construcción de las identidades en la música popular andina en Perú: un campo de disputa y negociación cultural.

Author

Pineau, Fanny, Mora R., Andrés, Pineau, Fanny, and Mora R., Andrés

Abstract

Este ensayo analiza la construcción y transformación de las identidades culturales en el Perú: un proceso complejo, multidimensional, conflictivo y dinámico, en el que intervienen referentes locales, nacionales y globales, políticos e históricos, que involucran a sujetos individuales y colectivos en disputa por la hegemonía. El caso de la música popular andina, que se desarrolla en el texto, es uno de los ámbitos que ofrecen mayores y más ricos elementos en el estudio de las identidades culturales.

Published
2011

42. Optimal target localization for subthalamic stimulation in patients with Parkinson disease.

Author

Welter, Marie-Laure, Schüpbach, Michael, Czernecki, Virginie, Karachi, Carine, Fernandez-Vidal, Sara, Golmard, Jean-Louis, Serra, Giulia, Navarro, Soledad, Welaratne, Arlette, Hartmann, Andréas, Mesnage, Valérie, Pineau, Fanny, Cornu, Philippe, Pidoux, Bernard, Worbe, Yulia, Zikos, Panayiotis, Grabli, David, Galanaud, Damien, Bonnet, Anne-Marie, and Belaid, Hayat

Published
2014
Full Text
View/download PDF

43. Behavioural disinhibition in frontotemporal dementia investigated within an ecological framework

Author

Tanguy, Delphine, Rametti-Lacroux, Armelle, Bouzigues, Arabella, Saracino, Dario, Le Ber, Isabelle, Godefroy, Valérie, Morandi, Xavier, Jannin, Pierre, Levy, Richard, Batrancourt, Bénédicte, Migliaccio, Raffaella, Batrancourt, Bénédicte, Azuar, Carole, Dubois, Bruno, Lecouturier, Karen, Araujo, Carla Matos, Janvier, Estelle, Jourdain, Aline, Rametti-Lacroux, Armelle, Coriou, Sophie, Brochard, Vanessa Batista, Gaudebout, Cécile, Ferrand-Verdejo, Johan, Bonnefous, Louis, Pochan-Leva, Flore, Jeanne, Lucie, Joulié, Mathilde, Provost, Myriam, Renaud, Rozenn, Hachemi, Sarah, Guillemot, Vincent, Bendetowicz, David, Carle, Guilhem, Socha, Julie, Pineau, Fanny, Marin, Frédéric, Liu, Yongjian, Mullot, Pierre, Mousli, Aymen, Blossier, Armelle, Visentin, Giulia, Tanguy, Delphine, Godefroy, Valérie, Sezer, Idil, Boucly, Mathilde, Cabrol-Douat, Blandine, Odobez, Raphaëlle, Marque, Constance, Tessereau-Barbot, Daphné, Raud, Anaïs, Funkiewiez, Aurélie, Chamayou, Céline, Cognat, Emmanuel, Le Bozec, Manon, Bouzigues, Arabella, Le Du, Vincent, Bombois, Stéphanie, Simard, Camille, Fulcheri, Paolo, Guitton, Hortense, Peltier, Caroline, Lejeune, François-Xavier, Jorgensen, Lars, Mariani, Louise-Laure, Corvol, Jean-Christophe, Valero-Cabre, Antoni, Garcin, Béatrice, Volle, Emmanuelle, Le Ber, Isabelle, Migliaccio, Raffaella, and Levy, Richard

Published
2022
Full Text
View/download PDF

44. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial

Author

Lhommée, Eugénie, Wojtecki, Lars, Czernecki, Virginie, Witt, Karsten, Maier, Franziska, Tonder, Lisa, Timmermann, Lars, Hälbig, Thomas D, Pineau, Fanny, Durif, Franck, Witjas, Tatiana, Pinsker, Marcus, Mehdorn, Maximilian, Sixel-Döring, Friederike, Kupsch, Andreas, Krüger, Rejko, Elben, Saskia, Chabardès, Stephan, Thobois, Stéphane, Brefel-Courbon, Christine, Ory-Magne, Fabienne, Regis, Jean-Marie, Maltête, David, Sauvaget, Anne, Rau, Jörn, Schnitzler, Alfons, Schüpbach, Michael, Schade-Brittinger, Carmen, Deuschl, Gunther, Houeto, Jean-Luc, and Krack, Paul

Subjects
610 Medicine & health, 3. Good health
Abstract

BACKGROUND Although subthalamic stimulation is a recognised treatment for motor complications in Parkinson's disease, reports on behavioural outcomes are controversial, which represents a major challenge when counselling candidates for subthalamic stimulation. We aimed to assess changes in behaviour in patients with Parkinson's disease receiving combined treatment with subthalamic stimulation and medical therapy over a 2-year follow-up period as compared with the behavioural evolution under medical therapy alone. METHODS We did a parallel, open-label study (EARLYSTIM) at 17 surgical centres in France (n=8) and Germany (n=9). We recruited patients with Parkinson's disease who were disabled by early motor complications. Participants were randomly allocated (1:1) to either medical therapy alone or bilateral subthalamic stimulation plus medical therapy. The primary outcome was mean change in quality of life from baseline to 2 years. A secondary analysis was also done to assess behavioural outcomes. We used the Ardouin Scale of Behavior in Parkinson's Disease to assess changes in behaviour between baseline and 2-year follow-up. Apathy was also measured using the Starkstein Apathy Scale, and depression was assessed with the Beck Depression Inventory. The secondary analysis was done in all patients recruited. We used a generalised estimating equations (GEE) regression model for individual items and mixed model regression for subscores of the Ardouin scale and the apathy and depression scales. This trial is registered with ClinicalTrials.gov, number NCT00354133. The primary analysis has been reported elsewhere; this report presents the secondary analysis only. FINDINGS Between July, 2006, and November, 2009, 251 participants were recruited, of whom 127 were allocated medical therapy alone and 124 were assigned bilateral subthalamic stimulation plus medical therapy. At 2-year follow-up, the levodopa-equivalent dose was reduced by 39% (-363·3 mg/day [SE 41·8]) in individuals allocated bilateral subthalamic stimulation plus medical therapy and was increased by 21% (245·8 mg/day [40·4]) in those assigned medical therapy alone (p

45. Quality of life predicts outcome of deep brain stimulation in early Parkinson disease

Author

Schüpbach, Michael, Tonder, Lisa, Schnitzler, Alfons, Krack, Paul, Rau, Joern, Hartmann, Andreas, Hälbig, Thomas D, Pineau, Fanny, Falk, Andrea, Paschen, Laura, Paschen, Stephen, Volkmann, Jens, Dafsari, Haidar S, Barbe, Michael T, Fink, Gereon R, Kühn, Andrea, Kupsch, Andreas, Schneider, Gerd-H, Seigneuret, Eric, Fraix, Valerie, Kistner, Andrea, Chaynes, P Patrick, Ory-Magne, Fabienne, Brefel-Courbon, Christine, Vesper, Jan, Wojtecki, Lars, Derrey, Stéphane, Maltête, David, Damier, Philippe, Derkinderen, Pascal, Sixel-Döring, Friederike, Trenkwalder, Claudia, Gharabaghi, Alireza, Wächter, Tobias, Weiss, Daniel, Pinsker, Marcus O, Regis, Jean-Marie, Witjas, Tatiana, Thobois, Stephane, Mertens, Patrick, Knudsen, Karina, Schade-Brittinger, Carmen, Houeto, Jean-Luc, Agid, Yves, Vidailhet, Marie, Timmermann, Lars, and Deuschl, Günther

Subjects
10. No inequality, 610 Medicine & health, humanities, nervous system diseases, 3. Good health
Abstract

OBJECTIVE To investigate predictors for improvement of disease-specific quality of life (QOL) after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications. METHODS We performed a secondary analysis of data from the previously published EARLYSTIM study, a prospective randomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-up with disease-specific QOL (39-item Parkinson's Disease Questionnaire summary index [PDQ-39-SI]) as the primary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration of motor complications, and disease severity measured at baseline with the Unified Parkinson's Disease Rating Scale (UPDRS) (UPDRS-III "off" and "on" medications, UPDRS-IV) were conducted to determine predictors of change in PDQ-39-SI. RESULTS PDQ-39-SI at baseline was correlated to the change in PDQ-39-SI after 24 months in both treatment groups (p < 0.05). The higher the baseline score (worse QOL) the larger the improvement in QOL after 24 months. No correlation was found for any of the other baseline characteristics analyzed in either treatment group. CONCLUSION Impaired QOL as subjectively evaluated by the patient is the most important predictor of benefit in patients with PD and early motor complications, fulfilling objective gold standard inclusion criteria for STN-DBS. Our results prompt systematically including evaluation of disease-specific QOL when selecting patients with PD for STN-DBS. CLINICALTRIALSGOV IDENTIFIER NCT00354133.

46. Trial of Deferiprone in Parkinson’s Disease

Author

Devos, David, Labreuche, Julien, Dušek, Petr, Post, Bart, Bloem, Bastiaan R, Berg, Daniela, Maetzler, Walter, Otto, Markus, Habert, Marie-Odile, Lehericy, Stéphane, Ferreira, Joaquim, Dodel, Richard, Rascol, Olivier, Tranchant, Christine, Eusebio, Alexandre, Thobois, Stéphane, Marques, Ana-Raquel, Meissner, Wassilios G, Ory-Magne, Fabienne, Walter, Uwe, de Bie, Rob M A, Gago, Miguel, Vilas, Dolores, Corvol, Jean-Christophe, Kulisevsky, Jaime, Januario, Cristina, Coelho, Miguel V S, Behnke, Stefanie, Worth, Paul, Seppi, Klaus, Ouk, Thavarak, Potey, Camille, Leclercq, Céline, Viard, Romain, Duhamel, Alain, Kuchcinski, Gregory, Lopes, Renaud, Pruvo, Jean-Pierre, Pigny, Pascal, Garçon, Guillaume, Simonin, Ophélie, Carpentier, Jessica, Rolland, Anne-Sophie, Nyholm, Dag, Scherfler, Christoph, Guyon Delannoy, Pauline, Mangin, Jean-François, Chupin, Marie, Bordet, Régis, Dexter, David T, Fradette, Caroline, Spino, Michael, Tricta, Fernando, Ayton, Scott, Bush, Ashley I, Devedjian, Jean-Christophe, Poewe, Werner, Duce, James A, Cabantchik, Ioav, Defebvre, Luc, Deplanque, Dominique, Moreau, Caroline, Group, FAIRPARK-II Study, Compta, Yaroslau, Pavese, Nicola, Růžička, Evžen, Basenau, Sandra, Beliveau, Vincent, Benchetrit, Eve, Best, Laura, Bloem, Bas, Bonicel, Robin, Boraud, T., Bordet, Regis, Bouca, Raquel, Bourdain, Frédéric, Bouzas, Jimena, Brefel-Courbon, Christine, Bubenheim, Michael, Burn, David, Bush, Ashley I, Cabantchik, Ioav, Calvas, Fabienne, Cámara, Ana, Campolongo, Antonia, Carrière, Nicolas, Chaigneau, Véronique, Matthieu, Collin, Compta, Yaroslau, Connelly, John, Cormier-Dequaire, Florence, Cranston, Amy, Dean, Rory, De Marzi, Roberto, Degos, Bertrand, Demotes, Jacques, Dellapina, Estelle, Deplanque, Dominique, Devedjian, Jean-Christophe, Devos, David, Dexter, David, Dodel, Richard, Dongmo, Carole, Duce, James, Duhamel, Alain, Dupouy, Julia, Dusek, Petr, El Mountassir, Fouzia, Eyvrard, Frédéric, Fernández, Manel, Ferreira, Joaquim, Forni, Gian Luca, Foster, Victoria, Foubert-Samier, Alexandra, Fradette, Caroline, Fréville, Laëtitia, Galitzky, Monique, Gaudebout, Cecile, Gelé, Patrick, Giladi, Nir, Grabli, David, Gleixner, Franck, Grolez, Guillaume, Guyon, Pauline, Habert, Marie-Odile, Harroch, Estelle, Hartmann, Andreas, Hirsch, Denise, Hisbergues, Michael, Hobert, Markus A, Hopfner, Franziska, Jurado, Camille, Kaiser, Andreas, Keen, Gill, Klaus, Seppi, Kouassi, Nadège, Labreuch, Julien, Lacomblez, Lucette, Lagha Boukbiza, Ouhaid, Lanthaler, Barbara, Lechatellier, Gilles, Le Forestier, Nadine, Lehmann, Fred, Lloret, Teresa, Le Naour, J., Le Toullec, Benjamin, Locatelli, Maxime, Löhle, Matthias, Lomeña, F., Longato, Nadine, Lützen, Ulf, McNichol, Ann, Maetzler, Corina, Maetzler, Walter, Mahlknecht, Philipp, Mangone, Graziella, Marín-Lahoz, Juan, Mariani, Louise-Laure, Marques, Ana, Matei, Mihaela, Matthias, Löhle, Maucourt Bacchi, Emilie, Meissner, Wassilios, Michon, Amelie, Moreau, Caroline, Nardocci, Nardo, Nosal, Florence, Nyholm, Dag, Oeckl, Patrick, Oravska, Irena, Ory, Fabienne, Otto, Markus, Ouk, Thavarak, Pagonabarraga, Javier, Pascual-Sedano, Berta, Peball, Marina, Phillips, Clélie, Pineau, Fanny, Planellas, Lluís, Pop-Ilieva, Chiesi, Rabier, Aurélie, Olivier, D., Riedel, Christian, Rodrigues, Maura, Roullet-Solignac, Isabelle, Rose, Christian, Rozova, Anna, Růžička, Evžen, Salis, Alexandra, Schäffer, Eva, Scherfler, Christoph, Schiefermeier, Natalia, Seppi, Klaus, Smagghe, Delphine, Silva, Tânia, Silva, Pedro, Socha, Julie, Souyris, Corinne, Spampinato, Umberto, Spino, Michael, Steel, Alison, Sweta, Bajaj, Thalamas, Claire, Teodor, Danaila, Teresa, Anna, Tison, François, Tolosa, Eduardo, Tricta, Fernando, Trifirò Trifirò, Gianluca, Vidailhet, Marie, Wang, Yi, Werkmann, Mario, Yilmas, Rezzak, You, Hana, Zeuner, Kirsten, Defebvre, Luc, Rascol, Olivier, Tranchant, Christine, Eusebio, Alexandre, Thobois, Stéphane, Corvol, Jean-Christophe, Durif, Franck, Meissner, Wassilos, Yaroslau, Compta, Vilas, Dolores, Kulisevsky, Jaime, Poewe, Werner, Ruzicka, Evzen, Gago, Miguel, Januario, Cristina, Vilhena Soares Coelho, Miguel, Berg, Daniela, Behnke, Stefanie, Walter, Uwe, Worth, Paul, Pavese, Nicola, Post, Bart, de Bie, Rob M A, Abbruzzese, Giovanni, Accart, Bertrand, Allain, Marie-Anne, Anheim, Mathieu, Ardigo, Diego, Aracil-Bolaños, Ignacio, Baba, Paul, Bakker, Martijn, Balzer-Geldsetzer, Monika, Bargalló, Núria, Barone, Paolo, Neurology, ANS - Neurodegeneration, and APH - Aging & Later Life

Subjects
administration & dosage [Deferiprone], Dopamine, Dopamine Agents, Medizin, Administration, Oral, Levodopa, Antiparkinson Agents, therapeutic use [Dopamine Agents], therapeutic use [Deferiprone], Deferiprone, metabolism [Iron], adverse effects [Deferiprone], Geriatrics/Aging, Parkinson Disease, General Medicine, Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3], Hematology/Oncology, chemistry [Substantia Nigra], adverse effects [Dopamine Agents], Disease Progression, administration & dosage [Dopamine Agents], physiopathology [Parkinson Disease], adverse effects [Iron Chelating Agents], Neutropenia, analysis [Iron], administration & dosage [Antiparkinson Agents], Iron, metabolism [Parkinson Disease], Neurology/Neurosurgery, therapeutic use [Levodopa], Iron Chelating Agents, pharmacology [Iron Chelating Agents], Double-Blind Method, adverse effects [Antiparkinson Agents], Genetics, diagnostic imaging [Substantia Nigra], metabolism [Substantia Nigra], Humans, ddc:610, diagnostic imaging [Brain], therapeutic use [Antiparkinson Agents], Brain Chemistry, pharmacology [Antiparkinson Agents], therapeutic use [Iron Chelating Agents], Hematology/Oncology General, chemically induced [Neutropenia], pharmacology [Deferiprone], drug therapy [Parkinson Disease], administration & dosage [Iron Chelating Agents], Geriatrics/Aging General, pharmacology [Dopamine Agents], drug effects [Substantia Nigra], Neuroscience
Abstract

Contains fulltext : 287484.pdf (Publisher’s version ) (Open Access) BACKGROUND: Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its effects on disease progression are unclear. METHODS: We conducted a multicenter, phase 2, randomized, double-blind trial involving participants with newly diagnosed Parkinson's disease who had never received levodopa. Participants were assigned (in a 1:1 ratio) to receive oral deferiprone at a dose of 15 mg per kilogram of body weight twice daily or matched placebo for 36 weeks. Dopaminergic therapy was withheld unless deemed necessary for symptom control. The primary outcome was the change in the total score on the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS; range, 0 to 260, with higher scores indicating more severe impairment) at 36 weeks. Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content measured with the use of magnetic resonance imaging was also an exploratory outcome. RESULTS: A total of 372 participants were enrolled; 186 were assigned to receive deferiprone and 186 to receive placebo. Progression of symptoms led to the initiation of dopaminergic therapy in 22.0% of the participants in the deferiprone group and 2.7% of those in the placebo group. The mean MDS-UPDRS total score at baseline was 34.3 in the deferiprone group and 33.2 in the placebo group and increased (worsened) by 15.6 points and 6.3 points, respectively (difference, 9.3 points; 95% confidence interval, 6.3 to 12.2; P

Published
2022
Full Text
View/download PDF

47. Prospective Acceptability of Digital Therapy for Major Depressive Disorder in France: Multicentric Real-Life Study.

Author

Amiot O, Sauvaget A, Alamome I, Bulteau S, Charpeaud T, Clair AH, Courtet P, Drapier D, Haffen E, Fakra E, Gaudeau-Bosma C, Gaillard A, Mouchabac S, Pineau F, Narboni V, Duburcq A, and Lecardeur L

Abstract

Background: Major depressive disorder is one of the leading causes of disability worldwide. Although most international guidelines recommend psychological and psychosocial interventions as first-line treatment for mild to moderate depression, access remains limited in France due to the limited availability of trained clinicians, high costs for patients in the context of nonreimbursement, and the fear of stigmatization. Therefore, online blended psychological treatment such as Deprexis could improve access to care for people with depression. It has several advantages, such as easy accessibility and scalability, and it is supported by evidence., Objective: This study aims to evaluate the real-life acceptability of Deprexis for people with depression in France outside of a reimbursement pathway., Methods: Deprexis Acceptability Study Measure in Real Life (DARE) was designed as a multicenter cross-sectional study in which Deprexis was offered to any patient meeting the inclusion criteria during the fixed inclusion period (June 2022-March 2023). Inclusion criteria were (1) depression, (2) age between 18 and 65 years, (3) sufficient French language skills, and (4) access to the internet with a device to connect to the Deprexis platform. Exclusion criteria were previous or current diagnoses of bipolar disorder, psychotic symptoms, and suicidal thoughts during the current episode. The primary objective was to measure the prospective acceptability of Deprexis, a new digital therapy. Secondary objectives were to examine differences in acceptability according to patient and clinician characteristics and to identify reasons for refusal. All investigators received video-based training on Deprexis before enrollment to ensure that they all had the same level of information and understanding of the program., Results: A total of 245 patients were eligible (n=159, 64.9% were women and n=138, 56.3% were single). The mean age was 40.7 (SD 14.1) years. A total of 78% (n=191) of the patients had moderate to severe depression (according to the Patient Health Questionnaire-9 [PHQ-9]). More than half of the population had another psychiatric comorbidity (excluding bipolar disorder, psychotic disorders, and suicidal ideation). A total of 33.9% (n=83) of patients accepted the idea of using Deprexis; the main reason for refusal was financial at 83.3% (n=135). Multivariate logistic regression identified factors that might favor the acceptability of Deprexis. Among these, being a couple, being treated with an antidepressant, or having a low severity level favored the acceptance of Deprexis., Conclusions: DARE is the first French study aiming at evaluating the prospective acceptability of digital therapy in the treatment of depression. The main reason for the refusal of Deprexis was financial. DARE will allow better identification of factors influencing acceptability in a natural setting. This study highlights the importance of investigating factors that may be associated with the acceptability of digital interventions, such as marital status, medication use, and severity of depression., (©Odile Amiot, Anne Sauvaget, Isabelle Alamome, Samuel Bulteau, Thomas Charpeaud, Anne-Hélène Clair, Philippe Courtet, Dominique Drapier, Emmanuel Haffen, Eric Fakra, Christian Gaudeau-Bosma, Adeline Gaillard, Stéphane Mouchabac, Fanny Pineau, Véronique Narboni, Anne Duburcq, Laurent Lecardeur. Originally published in JMIR Formative Research (https://formative.jmir.org), 20.05.2024.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results